Associate Professor Louise Bowman
|Tel||+44 (0)1865 743875|
- ASCEND: A Study of Cardiovascular Events iN Diabetes Research Group
- HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification Research Group
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Research Group
- Trials Methodology Research Group
- Research Regulation Research Group
BA, MBBS, MRCP, MD
Associate Professor of Clinical Trials and Epidemiology & Honorary Consultant Physician (Lipidology)
- Clinical Trial Service Unit
Dr. Louise Bowman is an Associate Professor at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics.
She is Joint Principal Investigator for the REVEAL study, an international clinical trial that aims to reliably assess the efficacy and safety of the new lipid-modifying agent, anacetrapib, in 30,000 high-risk individuals.
She is also Co-principal Investigator for the ASCEND trial which is studying the effects of aspirin and of omega-3 fatty acid supplementation for the primary prevention of cardiovascular disease in 15,000 people with diabetes. She was on the clinical team that coordinated the landmark MRC/BHF Heart Protection Study and the more recent SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial which evaluated an intensive cholesterol-lowering regimen compared with a standard regimen, and a folic-acid based homocysteine-lowering regimen with placebo in 12,000 heart attack survivors.
In addition to her work on clinical trials, she is also involved in a number of collaborative meta-analyses of trials and is a member of the Cholesterol Treatment Trialists’ Collaboration, the Antiplatelet Trialists’ Collaboration and the B-Vitamin Treatment Trialists’ Collaboration.
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190
Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol
Llewellyn-Bennett RE. et al, (2016), Systematic Reviews
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Aung T. et al, (2016), Trials, 17
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Heart Protection Study Collaborative Group None. et al, (2011), Lancet, 378, 2013 - 2020
Clinical trials of lipid-modifying agents: Design considerations
Bowman L. et al, (2011), Clinical Lipidology, 6, 109 - 116